Spring Bank Pharmaceuticals, Inc. Contracts & Agreements
73 Contracts & Agreements
- Business Finance (23 contracts)
- Business Operations (6)
- Human Resources (26)
- Intellectual Property (1)
- Mergers & Acquisitions (3)
- Real Estate (5)
- Uncategorized (9)
- Amendment No. 3 to Agreement and Plan of Merger, dated December 20, 2022 (Filed With SEC on December 21, 2022)
- Amendment No. 1 to Agreement and Plan of Merger, dated November 20, 2022 (Filed With SEC on November 21, 2022)
- Agreement and Plan of Merger, dated June 22, 2022, by and among invoX Pharma Limited, Fennec Acquisition Incorporated, Sino Biopharmaceutical Limited and F-star Therapeutics, Inc (Filed With SEC on June 23, 2022)
- Executive Service Agreement Amendment, dated as of April 6, 2022 by and between F-star Therapeutics Ltd and Eliot Forster, Ph.D (Filed With SEC on May 10, 2022)
- Consulting Agreement Amendment, dated April 6, 2022 by and between F-star Therapeutics, Inc and Darlene Deptula-Hicks (Filed With SEC on May 10, 2022)
- Service Agreement Amendment, dated April 6, 2022 by and between F-star Therapeutics Ltd and Neil Brewis, Ph.D (Filed With SEC on May 10, 2022)
- Addendum to the Indefinite-Term Employment Contract, dated as of June 25, 2021, by and between F-star Therapeutics, Inc. and Louis Kayitalire (Filed With SEC on May 10, 2022)
- Employment Agreement Amendment, dated April 6, 2022 by and between F-star Therapeutics, Inc and Louis Kayitalire M.D (Filed With SEC on May 10, 2022)
- Description of Registered Securities (Filed With SEC on March 15, 2022)
- Consulting Agreement, dated as of August 1, 2021, by and between F-star Therapeutics LLC and Darlene Deptula-Hicks (Filed With SEC on March 15, 2022)
- Form of Option Agreement under the 2019 Equity Incentive Plan (Filed With SEC on March 15, 2022)
- Form of Restricted Share Grant Notice and Agreement under the 2019 Equity Incentive Plan (Filed With SEC on March 15, 2022)
- Form of Performance Share Unit Grant Notice and Agreement under the 2019 Equity Incentive Plan (Filed With SEC on March 15, 2022)
- Form of Restricted Share Unit Grant Notice and Agreement under the 2019 Equity Incentive Plan (Filed With SEC on March 15, 2022)
- License Agreement between F-star Therapeutics, Inc. and Astrazeneca AB, dated as of July7, 2021 (Filed With SEC on November 10, 2021)
- Side Letter, dated June 30, 2021, to (a) the License and Collaboration Agreement, dated August 24, 2016, by and among BBB Holding Ltd (f/k/a F-star Gamma Limited, DBH ), F-star... (Filed With SEC on August 13, 2021)
- Form of Warrant issued under the Venture Loan and Security Agreement, dated April 1, 2021 (Filed With SEC on May 17, 2021)
- Venture Loan and Security Agreement, dated April 1, 2021, by and among F-star Therapeutics, Inc., as borrower, F-star Therapeutics Limited, as guarantor, and Horizon Technology... (Filed With SEC on May 17, 2021)
- Underwriting Agreement, dated May 6, 2021, between F-star Therapeutics, Inc. and SVB Leerink LLC (Filed With SEC on May 10, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on March 30, 2021)
- Lease Agreement between Are-Tech Square, LLC and F-star Biotechnology Ltd., dated December 31, 2018 (Filed With SEC on March 30, 2021)
- Tenancy Agreement between Babraham Bioscience Technologies Limited and F-star Biotechnology Limited, dated February 14, 2018 (Filed With SEC on March 30, 2021)
- Executive Service Agreement, dated as of October 1, 2018, as amended July 22, 2020, by and between F-star Biotechnology Limited and Eliot Forster, Ph.D (Filed With SEC on November 20, 2020)
- Consulting Agreement, dated as of May 1, 2019, by and between F-star Therapeutics LLC and Darlene Deptula-Hicks (Filed With SEC on November 20, 2020)
- Service Agreement, dated as of July 23, 2020, by and between F-star Biotechnology Limited and Neil Brewis, Ph.D (Filed With SEC on November 20, 2020)
- Employment Agreement, dated as of July 24, 2020, by and between F-star Therapeutics LLC and Louis Kayitalire, M.D (Filed With SEC on November 20, 2020)
- Form of Indemnification Agreement, by and between F-star Therapeutics, Inc. and each of its directors and executive officers (Filed With SEC on November 20, 2020)
- STING Agonist Contingent Value Rights Agreement, dated as of November 20, 2020, by and between Spring Bank Pharmaceuticals, Inc., F-star Therapeutics Limited, Computershare Inc.,... (Filed With SEC on November 20, 2020)
- STING Antagonist Contingent Value Rights Agreement, dated as of November 20, 2020, by and between Spring Bank Pharmaceuticals, Inc., F-star Therapeutics Limited, Computershare... (Filed With SEC on November 20, 2020)
- SPRING BANK PHARMACEUTICALS, INC. RETENTION AND BONUS AWARD AGREEMENT (Filed With SEC on November 3, 2020)
- SPRING BANK PHARMACEUTICALS, INC. RETENTION AND BONUS AWARD AGREEMENT (Filed With SEC on November 3, 2020)
- Spring Bank Pharmaceuticals, Inc. Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on June 25, 2020)
- Form of Restricted Stock Unit Agreement (Filed With SEC on May 7, 2020)
- Form of Retention Agreement (Filed With SEC on May 7, 2020)
- Form of Amended and Restated Warrant (Filed With SEC on April 13, 2020)
- Pay-Off Letter, dated April 8, 2020 (Filed With SEC on April 13, 2020)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 14, 2020)
- Loan and Security Agreement, dated September 3, 2019 (Filed With SEC on September 4, 2019)
- Form of Performance-Based Restricted Stock Unit Agreement under 2015 Stock Incentive Plan (Filed With SEC on March 11, 2019)
- Amended and Restated Non-Employee Director Compensation Policy, effective January 1, 2019 (Filed With SEC on March 11, 2019)
- Amendment No. 1 to Lease Agreement between 35 Parkwood Realty LLC and Spring Bank Pharmaceuticals, Inc., dated August 10, 2018 (Filed With SEC on October 25, 2018)
- Spring Bank Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on October 25, 2018)
- Underwriting Agreement, dated August 8, 2018, by and among the Company, Jefferies LLC and Piper Jaffray & Co (Filed With SEC on August 9, 2018)
- Spring Bank Pharmaceuticals, Inc. Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on June 19, 2018)
- Lease Agreement, dated October 4, 2017, between 35 Parkwood Realty LLC and Spring Bank Pharmaceuticals, Inc (Filed With SEC on October 5, 2017)
- Spring Bank Pharmaceuticals, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on August 18, 2017)
- 2,884,615 Shares Spring Bank Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 23, 2017)
- SPRING BANK PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of February 9, 2017) (Filed With SEC on February 14, 2017)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 21, 2016)
- Void after 5:00 p.m. (New York time) on the day of , 2021. (Filed With SEC on November 21, 2016)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 21, 2016)
- Spring Bank Pharmaceuticals, Inc. Common Stock Purchase Warrant (Void after [ ], 2021) (Filed With SEC on May 13, 2016)
- [] Shares Spring Bank Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 27, 2016)
- LEASE AGREEMENT (Filed With SEC on April 27, 2016)
- Spring Bank Pharmaceuticals, Inc. Common Stock Purchase Warrant (Void after , 2021) (Filed With SEC on April 27, 2016)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 27, 2016)
- [ ] Shares Spring Bank Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 9, 2016)
- THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE LEGENDS AND THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THISWARRANT (Filed With SEC on March 9, 2016)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENT BY AND... (Filed With SEC on January 15, 2016)
- INDEMNIFICATION AGREEMENT (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2014 Stock Incentive Plan (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. 2015 STOCK INCENTIVE PLAN (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on January 5, 2016)
- SPRING BANK PHARMACEUTICALS, INC. NONSTATUTORY STOCK OPTION AGREEMENT (Filed With SEC on January 5, 2016)
- LEASE ARTICLE I -PARTIES (Filed With SEC on January 5, 2016)
- 113 Cedar Street, Suite S-7, Milford, Massachusetts 01757 USA TEL ###-###-#### FAX ###-###-#### (Filed With SEC on January 5, 2016)
- EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on January 5, 2016)
- TRANSITION AGREEMENT (Filed With SEC on January 5, 2016)
- EXHIBIT A PAYMENTS SUBJECT TO SECTION 409A (Filed With SEC on January 5, 2016)
- EXHIBIT A PAYMENTS SUBJECT TO SECTION 409A (Filed With SEC on January 5, 2016)
- SPRING BANK TECHNOLOGIES, INC. AND MICROLOGIXBIOTECH, INC. STOCK PURCHASE AGREEMENT DECEMBER 17, 2003 STOCK PURCHASE AGREEMENT (Filed With SEC on January 5, 2016)